← Back to headlines
Ascendis Pharma's Navepegritide Approved by FDA for Achondroplasia
Ascendis Pharma has received FDA approval for its drug navepegritide, intended for the treatment of achondroplasia, a genetic bone growth disorder.
28 Feb, 03:31 — 28 Feb, 03:31
ℹOnly 1 source covers this story
